株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺動脈高血圧症の世界市場 - 規模、シェア、動向分析、予測:2019年~2026年

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Region, And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 408939
出版日 ページ情報 英文 122 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.90円で換算しております。
Back to Top
肺動脈高血圧症の世界市場 - 規模、シェア、動向分析、予測:2019年~2026年 Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Region, And Segment Forecasts, 2019 - 2026
出版日: 2019年04月17日 ページ情報: 英文 122 Pages
概要

世界の肺動脈高血圧症市場は、2019年から2026年の間に5.6%のCAGRで成長する見通しで、2026年には93億米ドルに達すると予測されています。肺動脈性高血圧症(PAH)の罹患率の増加、オーファンドラッグの開発に対する政府の支援が成長に拍車をかけています。

当レポートは世界の肺動脈高血圧症市場について調査しており、市場の変動、規制の枠組み、薬剤クラス・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査方法および範囲

  • 市場セグメントおよび範囲
  • 調査方法
  • 情報調達
  • 情報またはデータ分析
  • 市場の定式化および検証
  • モデル詳細
  • 二次文献のリスト
  • 一次文献のリスト
  • 略語のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメント別見通し
  • 競合の洞察

第3章 肺動脈高血圧症市場:変動、動向、および範囲

  • 市場リネージュの見通し
  • 洞察および成長の見通しのマッピング
  • 段階別:製品パイプライン分析
  • ユーザーの視点分析
  • 地域別/製品別/国別の主要エンドユーザー一覧
  • 規制の枠組み
  • 市場変動分析
  • 分析ツール

第4章 肺動脈高血圧症市場:薬剤クラス別セグメント分析

  • 定義および範囲
  • 市場シェア分析 2018年および2026年
  • プロスタサイクリンおよびプロスタサイクリン類似体
  • 可溶性グアニル酸シクラーゼ(Sgc)刺激剤
  • エンドセリン受容体拮抗薬(ERA)
  • ホスホジエステラーゼ5(Pde-5)

第5章 肺動脈高血圧症市場:地域分析

  • 定義および範囲
  • 市場のスナップショット
  • 市場シェアおよび主要企業 2018年
  • 市場シェア分析 2018年および2026年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東およびアフリカ

第6章 企業プロファイル

第7章 KOLの解説

  • 主な洞察
  • KOLビュー

第8章 おすすめ

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbrevations
  • Table 3 Product pipeline analysis
  • Table 4 Pipeline Analysis for the PAH Agents
  • Table 5 Monthly therapy cost for PAH agents
  • Table 6 Payer specific per patient per year monitoring cost by medication class
  • Table 7 Average selling prices for approved PAH agents in the U.S.
  • Table 8 Global Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 9 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 10 North America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 11 North America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 12 U.S. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 13 Canada Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 14 Europe Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 15 Europe Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 16 U.K. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 17 Germany Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 18 Spain Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 19 Italy Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 20 France Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 21 RoE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 22 Asia Pacific Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 23 Asia Pacific Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 24 Japan Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 25 China Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 26 India Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 27 Australia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 28 South Korea Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 29 RoAPAC Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 30 Latin America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 31 Latin America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 32 Brazil Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 33 Mexico Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 34 Argentina Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 35 RoLA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 36 MEA Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
  • Table 37 MEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 38 South Africa Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 39 Saudi Arabia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 40 UAE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
  • Table 41 RoMEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity Flow Analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Pulmonary arterial hypertension market snapshot (2018)
  • Fig. 11 Pulmonary arterial hypertension market segmentation
  • Fig. 12 Pulmonary arterial hypertension market: Strategy framework
  • Fig. 13 Market trends and outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Penetration & growth prospect mapping
  • Fig. 17 Market driver relevance analysis (Current & future impact)
  • Fig. 18 Global prevalence of PAH
  • Fig. 19 Global geriatric population, 2014 - 2024 (Million)
  • Fig. 20 Market restraint relevance analysis (Current & future impact)
  • Fig. 21 Patent term expiry of the key PAH brand
  • Fig. 22 Porter's five forces analysis
  • Fig. 23 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 24 Pulmonary arterial hypertension market drug class outlook: Segment dashboard
  • Fig. 25 Pulmonary arterial hypertension market: Drug class movement analysis
  • Fig. 26 Prostacyclin pathway
  • Fig. 27 Prostacyclin and prostacyclin analogs market, 2015 - 2026 (USD Million)
  • Fig. 28 Nitric oxide pathway
  • Fig. 29 Soluble guanylate cyclase (SGC) stimulators market, 2015 - 2026 (USD Million)
  • Fig. 30 Endothelial pathway
  • Fig. 31 Endothelin receptor antagonists (eras) market, 2015 - 2026 (USD Million)
  • Fig. 32 Nitric oxide pathway market, 2015 - 2026 (USD Million)
  • Fig. 33 Phosphodiesterase 5 (PDE-5) market, 2015 - 2026 (USD Million)
  • Fig. 34 Regional market place: Key takeaways
  • Fig. 35 Pulmonary Arterial Hypertension Market: Definition & Scope
  • Fig. 36 Regional Market Snapshot (Figures in USD Million, 2018)
  • Fig. 37 Regional Market Share, 2018 (USD Million)
  • Fig. 38 Regional outlook, 2018 & 2026
  • Fig. 39 North America market, 2015 - 2026 (USD Million)
  • Fig. 40 U.S. market, 2015 - 2026 (USD Million)
  • Fig. 41 Canada market, 2015 - 2026 (USD Million)
  • Fig. 42 Europe market, 2015 - 2026 (USD Million)
  • Fig. 43 U.K. market, 2015 - 2026 (USD Million)
  • Fig. 44 Germany market, 2015 - 2026 (USD Million)
  • Fig. 45 France market, 2015 - 2026 (USD Million)
  • Fig. 46 Italy market, 2015 - 2026 (USD Million)
  • Fig. 47 Spain market, 2015 - 2026 (USD Million)
  • Fig. 48 Asia Pacific market, 2015 - 2026 (USD Million)
  • Fig. 49 Japan market, 2015 - 2026 (USD Million)
  • Fig. 50 China market, 2015 - 2026 (USD Million)
  • Fig. 51 Australia market, 2015 - 2026 (USD Million)
  • Fig. 52 South Korea market, 2015 - 2026 (USD Million)
  • Fig. 53 Latin America market, 2015 - 2026 (USD Million)
  • Fig. 54 Brazil market, 2015 - 2026 (USD Million)
  • Fig. 55 Mexico market, 2015 - 2026 (USD Million)
  • Fig. 56 Argentina market, 2015 - 2026 (USD Million)
  • Fig. 57 MEA market, 2015 - 2026 (USD Million)
  • Fig. 58 South Africa market, 2015 - 2026 (USD Million)
  • Fig. 59 Saudi Arabia market, 2015 - 2026 (USD Million)
  • Fig. 60 UAE market, 2015 - 2026 (USD Million)
目次
Product Code: GVR-1-68038-997-5

The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to progress at a CAGR of 5.6% during the forecast period. Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Presence of a large geriatric population, with lower levels of immunity and prone to PAH and associated diseases, is a high impact-rendering driver for the PAH market. Though the beginning age for PAH is 45 years, it is often observed to occur in the population over 60 years of age.

Government initiatives, such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth. These are the two most vital acts that promote the ethical usage and distribution of orphan drugs. Development of orphan drugs is promoted by the National Organization of Rare Disorders and have a smaller market share.

Further key findings from the study suggest:

  • Based on drug class, prostacyclin and its analogs are projected to witness lucrative growth over the forecast period. The sales of these drugs are anticipated to grow sharply, primarily due to the expected growth in oral prostacyclin agents
  • North America held the leading market share of 58.3% in terms of revenue in 2018, attributed to supportive infrastructure for the development and distribution of high-quality therapies. Moreover, availability of reimbursement on PAH therapies supported the growth
  • Asia Pacific is anticipated to expand at the fastest CAGR of 6.7% over the forecast period due to its huge population base, rapid economic developments, and improving healthcare systems. Besides, high burden of diseases such as HIV that are responsible for the development of PAH foster the regional market growth

Major players operating in the pulmonary arterial hypertension market include: GlaxoSmithKline Plc.; Actelion Pharmaceuticals, Ltd.; United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. Companies enjoy the benefit of barrier in the entry to other firms due to high price interdependency.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Drug
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume Price Analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Pulmonary Arterial Hypertension Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, By Stage
    • 3.3.1 Registration Phase
  • 3.4 User Perspective Analysis
    • 3.4.1 Consumer Behavior Analysis
    • 3.4.2 Market Influencer Analysis
  • 3.5 List Of Key End-Users, By Region / By Product / By Country
  • 3.6 Regulatory Framework
    • 3.6.1 Reimbursement framework
      • 3.6.1.1 Therapy cost
      • 3.6.1.2 Therapy monitoring cost
      • 3.6.1.3 Average Selling Price
    • 3.6.2 Standards & Compliances
  • 3.7 Market Variable Analysis
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Incidents of Pulmonary Arterial Hypertension (PAH)
      • 3.7.1.2 Growing Geriatric Population
      • 3.7.1.3 Government Support for Development of Orphan Drugs
    • 3.7.2 Market Restraint Analysis
      • 3.7.2.1 Patent Expiration Of Key Molecules
    • 3.7.3 Industry Challenges
  • 3.8 Pulmonary Arterial Hypertension Market: Analysis Tools
    • 3.8.1 Porter's Five Forces Analysis
      • 3.8.1.1 Supplier Power: Low
      • 3.8.1.2 Buyer Power: moderate
      • 3.8.1.3 Substitution Threat: moderate
      • 3.8.1.4 Threat from new entrant: moderate
      • 3.8.1.5 Competitive rivalry: high
    • 3.8.2 Pestel Analysis
    • 3.8.3 Major Deals & Strategic Alliances Analysis
    • 3.8.4 Market Entry Strategies

Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Segment Analysis

  • 4.1 Pulmonary Arterial Hypertension Market: Definition & Scope
  • 4.2 Pulmonary Arterial Hypertension: Market Share Analysis, 2018 & 2026
  • 4.3 Prostacyclin and Prostacyclin Analogs
    • 4.3.1 Prostacyclin and Prostacyclin Analogs market, 2015 - 2026 (USD Million)
  • 4.4 Soluble Guanylate Cyclase (Sgc) Stimulators
    • 4.4.1 Soluble Guanylate Cyclase (Sgc) Stimulators Market, 2015 - 2026 (USD Million)
  • 4.5 Endothelin Receptor Antagonists (ERAs)
    • 4.5.1 Endothelin Receptor Antagonists (Eras) Market, 2015 - 2026 (USD Million)
  • 4.6 Phosphodiesterase 5 (Pde-5)
    • 4.6.1 Phosphodiesterase 5 (Pde-5) Market, 2015 - 2026 (USD Million)

Chapter 5 Pulmonary Arterial Hypertension Market: Regional Analysis

  • 5.1 Pulmonary Arterial Hypertension Market: Definition & Scope
  • 5.2 Regional Market Snapshot
  • 5.3 Regional Market Share and Leading Players, 2018
    • 5.3.1 North America
    • 5.3.2 Europe
    • 5.3.3 Asia Pacific
    • 5.3.4 Latin America
    • 5.3.5 Middle East & Africa
  • 5.4 Pulmonary Arterial Hypertension Market: Market Share Analysis, 2018 & 2026
  • 5.5 North America
    • 5.5.1 North America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.5.2 U.S.
      • 5.5.2.1 U.S. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.5.3 Canada
      • 5.5.3.1 Canada Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
  • 5.6 Europe
    • 5.6.1 Europe Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.6.2 U.K.
      • 5.6.2.1 U.K. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.6.3 Germany
      • 5.6.3.1 Germany Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.6.4 France
      • 5.6.4.1 France Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.6.5 Italy
      • 5.6.5.1 Italy Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.6.6 Spain
      • 5.6.6.1 Spain Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
  • 5.7 Asia Pacific
    • 5.7.1 Asia Pacific Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.7.2 Japan
      • 5.7.2.1 Japan Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.7.3 China
      • 5.7.3.1 China Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.7.4 Australia
      • 5.7.4.1 Australia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.7.5 South Korea
      • 5.7.5.1 South Korea Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
  • 5.8 Latin America
    • 5.8.1 Latin America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.8.2 Brazil
      • 5.8.2.1 Brazil Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.8.3 Mexico
      • 5.8.3.1 Mexico Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.8.4 Argentina
      • 5.8.4.1 Argentina Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
  • 5.9 MEA
    • 5.9.1 MEA Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.9.2 South Africa
      • 5.9.2.1 South Africa Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.9.3 Saudi Arabia
      • 5.9.3.1 Saudi Arabia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
    • 5.9.4 UAE
      • 5.9.4.1 UAE Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Company Profiles
    • 6.1.1 Actelion Pharmaceuticals, Ltd.
      • 6.1.1.1 Company overview
      • 6.1.1.2 Financial performance
      • 6.1.1.3 Product benchmarking
      • 6.1.1.4 Strategic initiatives
    • 6.1.2 Gilead Sciences, Inc.
      • 6.1.2.1 Company overview
      • 6.1.2.2 Financial PErformance
      • 6.1.2.3 Product benchmarking
      • 6.1.2.4 Strategic initiatives
    • 6.1.3 United Therapeutics Corporation
      • 6.1.3.1 Company overview
      • 6.1.3.2 Financial performance
      • 6.1.3.3 PAH Global Sale
      • 6.1.3.4 Product benchmarking
      • 6.1.3.5 Strategic initiatives
    • 6.1.4 Novartis International AG
      • 6.1.4.1 Company overview
      • 6.1.4.2 Financial Performance
      • 6.1.4.3 Product benchmarking
      • 6.1.4.4 Strategic initiatives
    • 6.1.5 GlaxoSmithKline Plc. (GSK)
      • 6.1.5.1 Company overview
      • 6.1.5.2 Financial performance
      • 6.1.5.3 Product benchmarking
    • 6.1.6 Pfizer, Inc.
      • 6.1.6.1 Company overview
      • 6.1.6.2 Product benchmarking
    • 6.1.7 Dong-A ST Co., Ltd.
      • 6.1.7.1 Company overview
      • 6.1.7.2 Financial performance
      • 6.1.7.3 Product benchmarking
      • 6.1.7.4 Strategic initiatives
    • 6.1.8 Merck Sharp & Dohme Corp.
      • 6.1.8.1 Company overview
      • 6.1.8.2 Finanical Performance
      • 6.1.8.3 Product benchmarking
      • 6.1.8.4 Strategic initiatives
    • 6.1.9 Bayer HealthCare
      • 6.1.9.1 Company overview
      • 6.1.9.2 Financial Performance
      • 6.1.9.3 Product benchmarking
      • 6.1.9.4 Strategic initiatives
    • 6.1.10 Arena Pharmaceuticals
      • 6.1.10.1 Company overview
      • 6.1.10.2 Financial performance
      • 6.1.10.3 Product benchmarking

Chapter 7 KOL Commentary

  • 7.1 Key Insights
  • 7.2 KOL Views

Chapter 8 Recommendations

Back to Top